This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Multiple sclerosis (MS) affects about 2.5 million people worldwide and about 400,000 in the United States.1 Although the disease course is variable, MS eventually causes considerable functional decline and morbidity as the disease progresses. Effective strategies in the care of patients with MS are multifaceted and involve early diagnosis and treatment in addition to symptom management, education, and providing a support system to improve or maintain patient adherence to MS therapies. It is essential that the clinician understand the value of early diagnosis and intervention, including the potential and relative benefits of disease-modifying therapies (DMTs). Clinicians can help patients with MS cope with symptoms resulting from MS, and also provide guidance for mitigating adverse effects (AEs) of therapy or supporting patient adherence to therapy when the patient questions the value of taking a DMT.
In this supplement, Patricia Coyle, MD, begins by addressing evidence that early neurologic damage in MS may occur before lesions are detectable on MRI. This is especially important, because the accumulation of lesions over time is …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Early treatment of multiple sclerosis to prevent neurologic damage
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
MRI criteria for MS in patients with clinically isolated syndromes
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis